Insilico Medicine, a clinical-stage biotechnology company powered by generative AI, announced the publication of a landmark study in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, revealing new evidence from the PandaOmics NAD mitophagy Alzheimer’s research program conducted in close collaboration with Norwegian researchers.
How This PandaOmics NAD Mitophagy Alzheimer’s Study Was Conducted
In collaboration with researchers from the University of Oslo and Akershus University Hospital led by Dr. Sofie Lautrup and Prof. Evandro Fei Fang, the team utilized Insilico’s proprietary AI biology platform, PandaOmics, alongside extensive experimental validation to uncover new molecular targets for Alzheimer’s disease and other neurodegenerative conditions. The international collaborative research team examined genes involved in mitochondrial function and NAD⁺ metabolism across 12 healthy brain regions, as well as in cerebrospinal fluid and blood, comparing gene-expression patterns during healthy aging with four major neurodegenerative diseases: Alzheimer’s, Parkinson’s, Huntington’s, and ALS.
Why the NAD⁺-Mitophagy Axis Matters
The research provides compelling evidence that impairment of the NAD⁺-mitophagy axis plays a central role in both healthy brain aging and neurodegeneration. By examining large-scale human data, the team demonstrated that interventions modulating mitochondrial metabolism hold profound potential for diagnosing and treating age-related cognitive decline.
The Biomarker Potential Within This PandaOmics NAD Mitophagy Alzheimer’s Research
The analysis revealed that widespread molecular changes in these pathways are already present during the early stages of disease progression. Notably, in Alzheimer’s and Parkinson’s diseases, several of these changes could be detected in blood samples, pointing to their immense potential as early blood-based biomarkers.
Why Detectability in Blood Matters Clinically
Identifying disease-relevant molecular changes in blood samples rather than requiring more invasive cerebrospinal fluid collection or brain tissue analysis could meaningfully lower the barrier to early detection, potentially enabling screening approaches that reach patients well before symptoms progress to more advanced stages.
How PandaOmics Prioritized Targets Within This Study
To translate these findings into therapeutic applications, researchers used PandaOmics to evaluate over 100 candidate genes involved in NAD⁺ and mitophagy pathways. This analysis prioritized five potential therapeutic targets for Alzheimer’s disease: ULK1, OPA1, LAMP2, MFN1, and ATP6V0E1.
What Dr. Lautrup Said About This Combined Approach
“Our results demonstrate the strength of combining human data and artificial intelligence with rigorous experimental validation, and offer new directions for the development of biomarkers and future interventions for Alzheimer’s disease,” said Dr. Sofie Lautrup, first and co-corresponding author.
Validating These PandaOmics NAD Mitophagy Alzheimer’s Targets in Preclinical Models
To verify the AI predictions, prioritized targets were evaluated across preclinical models, including C. elegans, a human Tau-mutant cell line, and APOE4/4 iPSC-derived cortical neurons. Functional modulation of these target genes directly altered disease pathology.
What Happened When Researchers Modulated These Genes
Enhancing mitochondrial fusion via OPA1 activation increased cell viability and significantly attenuated Tau phosphorylation in APOE4/4 cortical neurons. Conversely, knockdown of key mitophagy drivers, such as MFN1 and LAMP2, exacerbated Tau aggregation, underscoring the critical role of mitochondrial quality control in suppressing neurodegeneration.
What This Means for Insilico’s Broader AI Drug Discovery Approach
“This research once again demonstrates how our AI biology platform can rapidly unlock new possibilities in complex fields like neuroscience,” said Frank Pun, PhD, head of Insilico Hong Kong. “By uniting our computational capabilities with the molecular biology expertise of Dr. Evandro Fei Fang’s laboratory, we are successfully translating cutting-edge algorithms into tangible therapeutic candidates and biomarker strategies.”
Why This Combined AI-Wet Lab Model Matters for Drug Discovery
Drug discovery for neurodegenerative diseases has historically faced severe challenges, and this study’s approach, pairing AI-driven target prioritization with rigorous experimental validation across multiple model systems, offers a template for how computational biology and traditional laboratory science can work together to move candidate targets from broad genomic screening toward functionally validated therapeutic leads more efficiently.
What This PandaOmics NAD Mitophagy Alzheimer’s Research Means Going Forward
Given that five specific gene targets have now been functionally validated across multiple preclinical model systems, this research provides a concrete starting point for developing therapeutics aimed at enhancing mitochondrial quality control pathways in Alzheimer’s disease. Given the blood-detectable molecular changes identified across both Alzheimer’s and Parkinson’s diseases, researchers may find this NAD⁺-mitophagy axis offers a shared biomarker framework applicable across multiple neurodegenerative conditions rather than a single disease-specific pathway.
What to Watch Going Forward
As Insilico Medicine and its academic collaborators continue building on these findings, the field will likely watch for further preclinical work testing whether pharmacological activation of OPA1 or modulation of the other prioritized targets can be translated into viable drug candidates, and whether the blood-based biomarker signals identified here hold up in larger, more diverse patient cohorts. Given this study’s demonstration of how AI-driven target discovery combined with rigorous experimental validation can accelerate neurodegenerative disease research, this PandaOmics NAD mitophagy Alzheimer’s approach may serve as a model for similar AI-biology collaborations tackling other historically difficult-to-treat neurological conditions.
For more healthcare industry updates, insights and news, visit DistilINFO. Click here to subscribe to stay informed.
